Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Factor XIII (Catridecacog) in Cardiac Bypass Surgery
2008-006324-62Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of catridecacog in acquired factor XIII deficiency, Bleeding, coronary arteriosclerosis and 1 more (3 arms), sponsored by Novo Nordisk. Started Feb 2009; status: terminated.
02
Drugs
catridecacog
03
Conditions
acquired factor XIII deficiencyBleedingcoronary arteriosclerosisheart valve surgery
Beyond the preview
Go deeper on 2008-006324-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006324-62.